Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

NCT04812262 is registered in ClinicalTrials.gov with Neuraly, Inc. as lead sponsor.

NCT NCT04812262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04812262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
Lead sponsor
Neuraly, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 24, 2021
Completion date
February 14, 2023
Enrollment
255 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

nafld, overweight and obesity, type2 diabetes